Our work also provides useful insights into the biology of MET as a driver in NSCLC, supporting MET very‐high mRNA expression as a surrogate of amplification, and suggesting the relevance of MET mRNA levels in patients responding to MET‐TKIs. This evidence concerns the gene MET and non-small cell lung carcinoma.